Form 8-K PROTEON THERAPEUTICS For: Mar 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Proteon Therapeutics (PRTO) PT Lowered to $1 at Baird
March 28, 2019 11:19 AM EDTBaird analyst Michael Ulz lowered the price target on Proteon Therapeutics (NASDAQ: PRTO) to $1.00 (from $3.00) while maintaining a Neutral rating.
Ulz commented, "This morning, Proteon announced disappointing top-line results from the Phase 3 PATENCY-2 study of vonapanitase, indicating the co-primary endpoints of fistula use for... More
